• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Chiron Real Estate Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    3/3/26 6:30:36 AM ET
    $XRN
    Real Estate Investment Trusts
    Real Estate
    Get the next $XRN alert in real time by email
    false 0001533615 0001533615 2026-03-02 2026-03-02 0001533615 us-gaap:CommonStockMember 2026-03-02 2026-03-02 0001533615 us-gaap:SeriesAPreferredStockMember 2026-03-02 2026-03-02 0001533615 us-gaap:WarrantMember 2026-03-02 2026-03-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(D) OF THE 

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): March 3, 2026 (March 2, 2026)

     

    Chiron Real Estate Inc.

    (Exact name of registrant as specified in its charter)

     

    Maryland 001-37815 46-4757266

    (State or Other Jurisdiction

    of Incorporation)

    (Commission

    File Number)

    (I.R.S. Employer

    Identification No.)

     

    7373 Wisconsin Avenue, Suite 800

    Bethesda, MD

    20814

    (Address of Principal Executive
    Offices)

    (Zip Code)

     

    (202) 524-6851

    (Registrant’s Telephone Number, Including Area Code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class:   Trading Symbols:   Name of each exchange on which registered:
    Common Stock, par value $0.001 per share   XRN   NYSE
    Series A Preferred Stock, par value $0.001 per share   XRN PrA   NYSE
    Series B Preferred Stock, par value $0.001 per share   XRN PrB   NYSE

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On March 2, 2026, Chiron Real Estate LP (the “Operating Partnership”), as issuer, and Chiron Real Estate Inc., as a guarantor, entered into a Master Note and Guaranty Agreement (the “Agreement”) with NYL Investors LLC (“New York Life”) and certain affiliates of New York Life (collectively, the “Purchasers”).

     

    The Agreement establishes an uncommitted senior note facility pursuant to which the Operating Partnership may, from time to time, issue senior unsecured promissory notes (the “Notes”) in one or more series to the Purchasers in an aggregate outstanding principal amount of up to $150.0 million. The Agreement does not constitute a commitment by New York Life or any Purchaser to purchase any Notes, and each purchase of Notes is subject to the Purchasers’ sole discretion and satisfaction of customary conditions.

     

    Notes may be issued during a period ending on the earliest of (i) the third anniversary of the effective date of the Agreement, (ii) termination of the facility by either party upon written notice, (iii) termination following certain events of default, or (iv) acceleration of the Notes and termination of the facility.

     

    Each series of Notes issued under the Agreement will have a stated maturity of no more than ten years from the date of issuance. Interest rates for each issuance are determined at the time of issuance based on spreads over U.S. Treasury securities and are payable quarterly or semi-annually in arrears, as specified in the applicable issuance documentation. The minimum principal amount for any issuance is $10.0 million.

     

    The Notes are senior unsecured obligations of the Operating Partnership and rank pari passu with the Operating Partnership’s other senior unsecured indebtedness. The Operating Partnership may optionally prepay the Notes, in whole or in part, subject to payment of a customary make-whole amount.

     

    The above description of the terms and conditions of the Agreement is only a summary of the material terms and conditions of the Agreement and is not intended to be a complete description of the terms and conditions. All of the terms and conditions of the Agreement are set forth in the Agreement, which is filed as Exhibit 10.1 hereto, and is incorporated herein by reference.

     

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information disclosed above in Item 1.01 is incorporated by reference.

     

    Item 9.01Financial Statements and Exhibits

     

    (d) Exhibits

     

    Exhibit
    No.
    Description
    10.1* Master Note and Guaranty Agreement, dated March 2, 2026, by and among Chiron Real Estate LP, Chiron Real Estate Inc. and NYL Investors LLC and certain of its affiliates
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
    * Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10). The omitted information is not material and is the type of information that the registrant customarily and actually treats as private and confidential.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Chiron Real Estate Inc.
       
      By: /s/ Jamie A. Barber
        Jamie A. Barber
        Secretary and General Counsel
       
    Date: March 3, 2026

     

     

     

    Get the next $XRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XRN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $XRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

    Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most

    3/19/26 8:15:00 AM ET
    $ADTX
    $GMRE
    $XRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Chiron Real Estate Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    –Completes Corporate Rebrand– –Announces 2026 Strategic Objectives & Full Year 2026 Core FFO Guidance– –Announces Change from Quarterly to Monthly Dividends– Chiron Real Estate Inc. (NYSE:XRN) (the "Company" or "Chiron"), today announced financial results for the three and twelve months ended December 31, 2025 and other data. Mark Decker, Jr., Chief Executive Officer and President stated, "We're about eight months into the transformation of the business and we are making great progress. I'm grateful for all the hard work that's produced these early results and the support of our Board. We can see the business we want and a path to get there. As this quarter demonstrates, we have a s

    2/25/26 4:05:00 PM ET
    $XRN
    Real Estate Investment Trusts
    Real Estate

    $XRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by General Counsel and Secretary Barber Jamie Allen

    4 - Chiron Real Estate Inc. (0001533615) (Issuer)

    2/25/26 9:57:31 PM ET
    $XRN
    Real Estate Investment Trusts
    Real Estate

    SEC Form 4 filed by CFO and Treasurer Kiernan Robert J

    4 - Chiron Real Estate Inc. (0001533615) (Issuer)

    2/25/26 9:57:04 PM ET
    $XRN
    Real Estate Investment Trusts
    Real Estate

    SEC Form 4 filed by COO Holley Danica

    4 - Chiron Real Estate Inc. (0001533615) (Issuer)

    2/25/26 9:56:39 PM ET
    $XRN
    Real Estate Investment Trusts
    Real Estate

    $XRN
    SEC Filings

    View All

    SEC Form 424B5 filed by Chiron Real Estate Inc.

    424B5 - Chiron Real Estate Inc. (0001533615) (Filer)

    3/12/26 4:23:21 PM ET
    $XRN
    Real Estate Investment Trusts
    Real Estate

    SEC Form 424B5 filed by Chiron Real Estate Inc.

    424B5 - Chiron Real Estate Inc. (0001533615) (Filer)

    3/12/26 4:21:35 PM ET
    $XRN
    Real Estate Investment Trusts
    Real Estate

    Chiron Real Estate Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Chiron Real Estate Inc. (0001533615) (Filer)

    3/3/26 6:30:36 AM ET
    $XRN
    Real Estate Investment Trusts
    Real Estate

    $XRN
    Leadership Updates

    Live Leadership Updates

    View All

    Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

    Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most

    3/19/26 8:15:00 AM ET
    $ADTX
    $GMRE
    $XRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate